Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manish R Patel

Showing results (91-100 of 167) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation StudyAlex F Herrera, Manish R Patel, John M Burke, et al.
Leukemia & Lymphoma|February 8, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphomaSteven M Horwitz, Tatyana A Feldman, Jing Christine Ye, et al.
British Journal of Cancer|December 9, 2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10Rebecca S Kristeleit, Yvette Drew, Amit M Oza, et al.
The Lancet. Oncology|February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyHoward A Burris, Ian W Flinn, Manish R Patel, et al.
Breast Cancer Research : BCR|July 2, 2025
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study resultsErika P Hamilton, Manish R Patel, Virginia F Borges, et al.
Journal of Geophysical Research. Planets|July 22, 2022
Vertical Aerosol Distribution and Mesospheric Clouds From ExoMars UVISPaul M Streeter, Graham Sellers, Michael J Wolff, et al.
Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.
The Lancet. Oncology|April 2, 2026
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trialMelissa L Johnson, Manish R Patel, Gerald S Falchook, et al.
The Lancet. Oncology|December 9, 2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialManish R Patel, John Ellerton, Jeffrey R Infante, et al.
Nature Communications|February 25, 2025
Detection of ferrihydrite in Martian red dust records ancient cold and wet conditions on MarsAdomas Valantinas, John F Mustard, Vincent Chevrier, et al.
Pageof 17

Showing results (91-100 of 167) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation StudyAlex F Herrera, Manish R Patel, John M Burke, et al.
Leukemia & Lymphoma|February 8, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphomaSteven M Horwitz, Tatyana A Feldman, Jing Christine Ye, et al.
British Journal of Cancer|December 9, 2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10Rebecca S Kristeleit, Yvette Drew, Amit M Oza, et al.
The Lancet. Oncology|February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyHoward A Burris, Ian W Flinn, Manish R Patel, et al.
Breast Cancer Research : BCR|July 2, 2025
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study resultsErika P Hamilton, Manish R Patel, Virginia F Borges, et al.
Journal of Geophysical Research. Planets|July 22, 2022
Vertical Aerosol Distribution and Mesospheric Clouds From ExoMars UVISPaul M Streeter, Graham Sellers, Michael J Wolff, et al.
Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.
The Lancet. Oncology|April 2, 2026
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trialMelissa L Johnson, Manish R Patel, Gerald S Falchook, et al.
The Lancet. Oncology|December 9, 2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialManish R Patel, John Ellerton, Jeffrey R Infante, et al.
Nature Communications|February 25, 2025
Detection of ferrihydrite in Martian red dust records ancient cold and wet conditions on MarsAdomas Valantinas, John F Mustard, Vincent Chevrier, et al.
Pageof 17